Biosino Bio-Technology and Science Incorporation Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Peng Chen
Chief executive officer
CN¥1.5m
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 3.9yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Biosino Bio-Technology and Science Incorporation (HKG:8247) Has Debt But No Earnings; Should You Worry?
Oct 06
Biosino Bio-Technology and Science Incorporation's (HKG:8247) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Aug 07Here's Why Some Shareholders May Not Be Too Generous With Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation This Year
May 23Biosino Bio-Technology and Science Incorporation's (HKG:8247) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Biosino Bio-Technology and Science Incorporation's (HKG:8247) Business And Shares Still Trailing The Industry
Oct 31Biosino Bio-Technology and Science Incorporation's (HKG:8247) 26% Dip In Price Shows Sentiment Is Matching Revenues
Jun 27Shareholders Will Probably Be Cautious Of Increasing Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation At The Moment
Jun 21Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 46%
Apr 22Is Biosino Bio-Technology and Science Incorporation (HKG:8247) Using Debt In A Risky Way?
Apr 01Biosino Bio-Technology and Science Incorporation's (HKG:8247) 31% Dip In Price Shows Sentiment Is Matching Revenues
Feb 08Some Confidence Is Lacking In Biosino Bio-Technology and Science Incorporation (HKG:8247) As Shares Slide 38%
Jul 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -CN¥47m |
| Mar 31 2025 | n/a | n/a | -CN¥45m |
| Dec 31 2024 | CN¥2m | CN¥2m | -CN¥43m |
| Sep 30 2024 | n/a | n/a | -CN¥34m |
| Jun 30 2024 | n/a | n/a | -CN¥19m |
| Mar 31 2024 | n/a | n/a | -CN¥13m |
| Dec 31 2023 | CN¥2m | CN¥2m | -CN¥12m |
| Sep 30 2023 | n/a | n/a | -CN¥9m |
| Jun 30 2023 | n/a | n/a | CN¥2m |
| Mar 31 2023 | n/a | n/a | CN¥4m |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥8m |
| Sep 30 2022 | n/a | n/a | CN¥2m |
| Jun 30 2022 | n/a | n/a | -CN¥2m |
| Mar 31 2022 | n/a | n/a | -CN¥1m |
| Dec 31 2021 | CN¥95k | CN¥95k | -CN¥1m |
Compensation vs Market: Peng's total compensation ($USD214.63K) is about average for companies of similar size in the Hong Kong market ($USD233.61K).
Compensation vs Earnings: Peng's compensation has been consistent with company performance over the past year.
CEO
Peng Chen (50 yo)
Mr. Chen Peng has been President of Biosino Bio-Technology and Science Incorporation since December 7, 2021 and has been its Executive Director since My 25, 2023 . Mr. Chen has ample experience in corporat...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 2.5yrs | no data | no data | |
| President & Executive Director | 2.5yrs | CN¥1.53m | no data | |
| Non-Executive Director | 2.5yrs | no data | no data | |
| Independent Non-Executive Director | 1.4yrs | CN¥30.00k | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Supervisor | 4.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.8yrs | CN¥60.00k | no data | |
| Non-Executive Director | 2.5yrs | no data | no data | |
| Non-Executive Vice Chairman of the Board | 2.2yrs | no data | no data | |
| Chairman of the Supervisory Committee | 1.4yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: 8247's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/11 01:27 |
| End of Day Share Price | 2025/11/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biosino Bio-Technology and Science Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| T. J. Hsu | KGI Securities Co. Ltd. |